CR8102A - Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa - Google Patents
Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasaInfo
- Publication number
- CR8102A CR8102A CR8102A CR8102A CR8102A CR 8102 A CR8102 A CR 8102A CR 8102 A CR8102 A CR 8102A CR 8102 A CR8102 A CR 8102A CR 8102 A CR8102 A CR 8102A
- Authority
- CR
- Costa Rica
- Prior art keywords
- preparation
- derivatives
- quinazolina
- pirazolo
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Se revelan derivados de pirazolo- quinazolina de formula (Ia) o (Ib) como se definen en la memoria y sales farmaceuticamente aceptables de los mismos, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden; los compuestos de la invencion pueden ser utiles, en terapeutica, en el tratamiento de enfermedades asociadas con una actividad desregulada de la proteina quinasa, como cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47266103P | 2003-05-22 | 2003-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8102A true CR8102A (es) | 2006-08-09 |
Family
ID=33476970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8102A CR8102A (es) | 2003-05-22 | 2005-11-22 | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa |
Country Status (36)
Country | Link |
---|---|
US (8) | US7482354B2 (es) |
EP (1) | EP1636236B1 (es) |
JP (1) | JP5043432B2 (es) |
KR (1) | KR101084871B1 (es) |
CN (2) | CN1826343A (es) |
AP (1) | AP2064A (es) |
AR (2) | AR044543A1 (es) |
AU (1) | AU2004240772B2 (es) |
BR (2) | BRPI0410563B8 (es) |
CA (1) | CA2526578C (es) |
CO (1) | CO5721006A2 (es) |
CR (1) | CR8102A (es) |
CY (1) | CY1114708T1 (es) |
DK (1) | DK1636236T3 (es) |
EA (1) | EA010904B1 (es) |
EC (1) | ECSP056194A (es) |
ES (1) | ES2436524T3 (es) |
GE (1) | GEP20094664B (es) |
HR (1) | HRP20050967B8 (es) |
IL (1) | IL172046A (es) |
IS (1) | IS2939B (es) |
ME (1) | ME00142B (es) |
MX (1) | MXPA05012573A (es) |
MY (1) | MY142019A (es) |
NO (1) | NO334992B1 (es) |
NZ (1) | NZ543661A (es) |
OA (1) | OA13170A (es) |
PL (1) | PL1636236T3 (es) |
PT (1) | PT1636236E (es) |
RS (2) | RS52899B (es) |
SI (1) | SI1636236T1 (es) |
TN (1) | TNSN05298A1 (es) |
TW (1) | TWI349672B (es) |
UA (1) | UA80763C2 (es) |
WO (1) | WO2004104007A1 (es) |
ZA (1) | ZA200509486B (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00142B (me) * | 2003-05-22 | 2010-10-10 | Nerviano Medical Sciences Srl | Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
ITMI20041033A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2007090794A1 (en) * | 2006-02-10 | 2007-08-16 | Nerviano Medical Sciences S.R.L. | Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic |
CN101443002B (zh) * | 2006-05-09 | 2012-03-21 | 诺瓦提斯公司 | 包含铁螯合剂和抗肿瘤药的组合及其用途 |
WO2007149395A2 (en) * | 2006-06-20 | 2007-12-27 | Amphora Discovery Corporation | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer |
US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
AU2007336281B2 (en) | 2006-12-21 | 2013-05-30 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
UA102219C2 (ru) * | 2006-12-21 | 2013-06-25 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы |
EP2213673B1 (en) | 2007-10-23 | 2013-06-05 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
CN101945867A (zh) * | 2007-12-19 | 2011-01-12 | 安姆根有限公司 | 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物 |
EP2278973B1 (en) * | 2008-04-07 | 2011-11-02 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
TWI426074B (zh) * | 2008-04-30 | 2014-02-11 | Nerviano Medical Sciences Srl | 5-(2-胺基-嘧啶-4-基)-2-芳基-1h-吡咯-3-羧醯胺之製造方法 |
MX2010013843A (es) * | 2008-06-26 | 2011-01-21 | Nerviano Medical Sciences Srl | Pirazolo-quinazolinas. |
JP5579715B2 (ja) * | 2008-07-29 | 2014-08-27 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ |
US8946226B2 (en) * | 2008-07-29 | 2015-02-03 | Nerviano Medical Sciences S.R.L. | Use of CDK inhibitor for the treatment of glioma |
EP2350084B1 (en) * | 2008-10-17 | 2015-06-24 | Boehringer Ingelheim International GmbH | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
EP2376084B1 (en) | 2008-11-24 | 2013-07-17 | Nerviano Medical Sciences S.r.l. | CDK inhibitor for the treatment of mesothelioma |
IT1395724B1 (it) * | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
US8580793B2 (en) * | 2009-03-20 | 2013-11-12 | Nerviano Medical Services S.R.L. | Use of kinase inhibitor for the treatment of thymoma |
US9243000B2 (en) | 2009-04-22 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Thia-triaza-indacenes |
CN102428086B (zh) * | 2009-04-29 | 2014-08-20 | 内尔维阿诺医学科学有限公司 | Cdk抑制剂的盐类 |
AR076784A1 (es) * | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
CN103626777B (zh) * | 2009-07-29 | 2015-10-21 | 内尔维阿诺医学科学有限公司 | Plk抑制剂的盐类 |
CA2787785C (en) * | 2010-01-28 | 2018-03-06 | President And Fellows Of Harvard College | Compositions and methods for enhancing proteasome activity |
US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
EP2598508B1 (en) | 2010-07-30 | 2015-04-22 | Nerviano Medical Sciences S.r.l. | Isoxazolo-quinazolines as modulators of protein kinase activity |
BR112013006671A2 (pt) | 2010-09-23 | 2016-06-07 | Syngenta Participations Ag | microbiocidas21 |
HUE030714T2 (en) * | 2010-10-25 | 2017-05-29 | G1 Therapeutics Inc | CDK inhibitors |
RU2652638C2 (ru) * | 2010-12-17 | 2018-04-28 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы |
CN103339134B (zh) * | 2011-01-26 | 2015-12-23 | 内尔维阿诺医学科学有限公司 | 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用 |
US8916577B2 (en) * | 2011-01-26 | 2014-12-23 | Nerviano Medical Sciences S.R.L. | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors |
WO2012117021A2 (en) | 2011-03-03 | 2012-09-07 | Syngenta Participations Ag | Novel microbiocidal oxime ethers |
US8623885B2 (en) | 2011-03-23 | 2014-01-07 | Amgen Inc. | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 |
EP2707101B1 (en) | 2011-05-12 | 2019-02-13 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
WO2013092460A1 (en) | 2011-12-20 | 2013-06-27 | Syngenta Participations Ag | Cyclic bisoxime microbicides |
US9150578B2 (en) | 2012-01-23 | 2015-10-06 | Boehringer Ingelheim International Gmbh | 5,8-dihydro-6H-pyrazolo[3,4-h]quinazolines as IGF-1R/IR inhibitors |
EP2641901A1 (en) | 2012-03-22 | 2013-09-25 | Syngenta Participations AG. | Novel microbiocides |
CN104870446B (zh) | 2012-11-07 | 2019-08-13 | 内尔维阿诺医学科学有限公司 | 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途 |
WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
PT2968290T (pt) | 2013-03-15 | 2019-11-27 | G1 Therapeutics Inc | Protecção transitória de células normais durante a quimioterapia |
CN105407723A (zh) | 2013-03-15 | 2016-03-16 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
JP6518690B2 (ja) | 2014-04-07 | 2019-05-22 | ネザーランズ トランスレーショナル リサーチ センター ビー.ブイ. | (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン |
WO2015161287A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of normal cells during chemotherapy |
US10555931B2 (en) | 2014-05-28 | 2020-02-11 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
JP7000321B2 (ja) | 2015-07-17 | 2022-02-10 | アンスティテュ・パストゥール | 衛星細胞の自己再生および/または分化の促進剤としての使用のための5-ヒドロキシトリプタミン1b受容体刺激剤 |
KR20190038840A (ko) | 2016-07-15 | 2019-04-09 | 앵스띠뛰 파스퇴르 | 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제 |
CA3039012C (en) * | 2016-11-11 | 2021-08-24 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof |
US11117901B2 (en) | 2017-07-11 | 2021-09-14 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
KR20200038286A (ko) * | 2017-08-11 | 2020-04-10 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물 |
US20220363690A1 (en) * | 2019-09-05 | 2022-11-17 | Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. | Isoxazolo[5,4-h]quinazoline compounds as protein kinase inhibitors |
WO2021084541A1 (en) * | 2019-10-31 | 2021-05-06 | Sol-Gel Technologies Ltd. | Treatment of hair loss disorders with a topical egfr inhibitor |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN114685520A (zh) * | 2020-12-25 | 2022-07-01 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
CN116528871A (zh) * | 2020-12-31 | 2023-08-01 | 恒元生物医药科技(苏州)有限公司 | 一种吡唑并喹唑啉类化合物、其制备方法及应用 |
JP2024505714A (ja) * | 2021-02-08 | 2024-02-07 | メッドシャイン ディスカバリー インコーポレイテッド | 5,6-ジドヒロチエノ[3,4-h]キナゾリン系化合物 |
CN113527310B (zh) * | 2021-07-30 | 2022-09-23 | 上海市肺科医院 | 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用 |
WO2023104178A1 (zh) * | 2021-12-10 | 2023-06-15 | 山东绿叶制药有限公司 | 蛋白激酶抑制剂及其制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2119975A (en) * | 1936-08-26 | 1938-06-07 | Beatrice S Nazel | Fluid pressure hammer |
JP3907220B2 (ja) * | 1994-06-30 | 2007-04-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 複素環含有化合物 |
EP0831829B1 (en) | 1995-06-07 | 2003-08-20 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
EP0946523A1 (en) | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
KR20020060160A (ko) | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
NZ524475A (en) | 2000-08-10 | 2004-11-26 | Pharmacia Italia S | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
ES2299501T3 (es) * | 2000-08-11 | 2008-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos heterociclicos utiles como inhibidores de tirosina-quinasas. |
JP2004517840A (ja) | 2000-11-27 | 2004-06-17 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 |
MXPA03006478A (es) | 2001-01-26 | 2003-09-22 | Pharmacia Italia Spa | Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales. |
JP2005501083A (ja) * | 2001-08-10 | 2005-01-13 | ファルマシア・コーポレーション | 炭酸脱水酵素阻害剤 |
US20030100594A1 (en) * | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
EP1432416B1 (en) | 2001-09-26 | 2011-01-19 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
AU2003225580A1 (en) * | 2002-02-19 | 2003-09-09 | Pharmacia Corporation | Tricyclic pyrazole derivatives for the treatment of inflammation |
ME00142B (me) | 2003-05-22 | 2010-10-10 | Nerviano Medical Sciences Srl | Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze |
AU2007336281B2 (en) * | 2006-12-21 | 2013-05-30 | Nerviano Medical Sciences S.R.L. | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
-
2004
- 2004-04-27 ME MEP-2008-259A patent/ME00142B/me unknown
- 2004-04-27 JP JP2006530168A patent/JP5043432B2/ja not_active Expired - Lifetime
- 2004-04-27 EP EP04741483.4A patent/EP1636236B1/en not_active Expired - Lifetime
- 2004-04-27 DK DK04741483.4T patent/DK1636236T3/da active
- 2004-04-27 NZ NZ543661A patent/NZ543661A/xx unknown
- 2004-04-27 CA CA2526578A patent/CA2526578C/en not_active Expired - Lifetime
- 2004-04-27 UA UAA200512347A patent/UA80763C2/uk unknown
- 2004-04-27 RS RS20050944A patent/RS52899B/en unknown
- 2004-04-27 AP AP2005003452A patent/AP2064A/xx active
- 2004-04-27 ES ES04741483.4T patent/ES2436524T3/es not_active Expired - Lifetime
- 2004-04-27 CN CNA2004800210752A patent/CN1826343A/zh active Pending
- 2004-04-27 EA EA200501849A patent/EA010904B1/ru unknown
- 2004-04-27 KR KR1020057022355A patent/KR101084871B1/ko active IP Right Grant
- 2004-04-27 MX MXPA05012573A patent/MXPA05012573A/es active IP Right Grant
- 2004-04-27 BR BRPI0410563A patent/BRPI0410563B8/pt active IP Right Grant
- 2004-04-27 AU AU2004240772A patent/AU2004240772B2/en active Active
- 2004-04-27 OA OA1200500329A patent/OA13170A/fr unknown
- 2004-04-27 GE GEAP20049128A patent/GEP20094664B/en unknown
- 2004-04-27 RS YUP-2005/0944A patent/RS20050944A/sr unknown
- 2004-04-27 PL PL04741483T patent/PL1636236T3/pl unknown
- 2004-04-27 SI SI200432118T patent/SI1636236T1/sl unknown
- 2004-04-27 PT PT47414834T patent/PT1636236E/pt unknown
- 2004-04-27 CN CN2010105863199A patent/CN102079746A/zh active Pending
- 2004-04-27 BR BR122019010200A patent/BR122019010200B8/pt active IP Right Grant
- 2004-04-27 US US10/557,565 patent/US7482354B2/en not_active Expired - Lifetime
- 2004-04-27 WO PCT/EP2004/050612 patent/WO2004104007A1/en active Application Filing
- 2004-05-04 TW TW093112449A patent/TWI349672B/zh active
- 2004-05-13 MY MYPI20041795A patent/MY142019A/en unknown
- 2004-05-20 AR ARP040101748A patent/AR044543A1/es active IP Right Grant
-
2005
- 2005-11-18 IS IS8132A patent/IS2939B/is unknown
- 2005-11-20 IL IL172046A patent/IL172046A/en active IP Right Grant
- 2005-11-21 TN TNP2005000298A patent/TNSN05298A1/fr unknown
- 2005-11-21 HR HRP20050967AA patent/HRP20050967B8/hr active IP Right Grant
- 2005-11-21 NO NO20055496A patent/NO334992B1/no unknown
- 2005-11-22 CR CR8102A patent/CR8102A/es unknown
- 2005-11-22 CO CO05118410A patent/CO5721006A2/es active IP Right Grant
- 2005-11-23 ZA ZA200509486A patent/ZA200509486B/xx unknown
- 2005-11-30 EC EC2005006194A patent/ECSP056194A/es unknown
-
2008
- 2008-10-31 US US12/262,933 patent/US8541429B2/en active Active
-
2013
- 2013-08-21 US US13/972,659 patent/US8981089B2/en active Active
- 2013-12-09 CY CY20131101108T patent/CY1114708T1/el unknown
-
2015
- 2015-02-18 US US14/625,093 patent/US9464090B2/en not_active Expired - Lifetime
- 2015-11-20 AR ARP150103780A patent/AR102722A2/es unknown
-
2016
- 2016-09-06 US US15/256,916 patent/US9637497B2/en not_active Expired - Lifetime
-
2017
- 2017-03-23 US US15/467,323 patent/US10280176B2/en not_active Expired - Lifetime
-
2019
- 2019-03-04 US US16/291,323 patent/US20190194214A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/084,862 patent/US20210300935A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
ECSP056246A (es) | DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA | |
GT200500020A (es) | Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
TW200833693A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
UY30327A1 (es) | Nuevos compuestos ii | |
UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
UY32203A (es) | Amino pirimidinas y su uso en terapia | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
CU23596A3 (es) | Derivados de pirazol-quinazolina y proceso para su preparación | |
CU23566B7 (es) | Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa | |
UY28409A1 (es) | Derivados de pirrolo (3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparación y composiciones farmaceuticas que los comprenden | |
CU20060152A7 (es) | Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa | |
CR9817A (es) | Compuestos terapeuticos |